Reuters logo
BRIEF-Enanta says Abbvie’s Maviret approved in Japan for the treatment of all major genotypes of chronic hepatitis c
September 27, 2017 / 10:43 AM / in 22 days

BRIEF-Enanta says Abbvie’s Maviret approved in Japan for the treatment of all major genotypes of chronic hepatitis c

Sept 27 (Reuters) - Enanta Pharmaceuticals Inc

* Enanta announces that Abbvie’s Maviret (glecaprevir/pibrentasvir) received approval in Japan for the treatment of all major genotypes (GT1-6) of chronic hepatitis c

* Enanta Pharmaceuticals - co expects to receive $15 million milestone payment from Abbvie in quarter ending Dec 31, 2017, upon price reimbursement approval of Maviret in Japan​

* Enanta Pharma - expects to get $15 million milestone payment from Abbvie in quarter ending Dec 31, 2017, upon Japan​ price reimbursement approval of Maviret

* Enanta Pharmaceuticals -‍in Japan, Maviret is also approved as 12-week option for patients infected with GT3-6, patients with specific challenges​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below